Although polymorphisms, such as FCGR3A-V158F, have been extensively studied14, an overview of FCGR3A-V158F polymorphisms within the Egyptian population is lacking and the association of this polymorphism with trastuzumab benefit for patients with breast cancer is not clear. This evidence concerns the gene FCGR3A and breast carcinoma.